|
1) 西森 功, 岡崎和一, 川 茂之, 他. 自己免疫性膵炎の治療についての実態調査. 胆と膵. 2007; 28: 961-6
|
|
|
|
2) Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid therapy for autoimmune pancreatitis. Gut. 2009; 58: 1504-7
|
|
|
|
|
3) Wakabayashi T, Kawaura Y, Satomura Y, et al. Long-term prognosis of duct-narrowing chronic pancreatitis. Strategy for steroid treatment. Pancreas. 2005; 30: 31-9
|
|
|
|
|
|
4) Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005; 5: 234-40
|
|
|
|
|
|
5) Kubota K, Iida H, Fujisawa T, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007; 66: 1142-51
|
|
|
|
|
|
6) Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol. 2006; 41: 613-25
|
|
|
|
|
|
7) Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007; 56: 1719-24
|
|
|
|
|
|
8) Chari ST. Current concepts in the treatment of autoimmune pancreatitis. JOP. 2007; 8: 1-3
|
|
|
|
|
|
9) Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006; 4: 1010-6
|
|
|
|
|
|
10) Kwon S, Kim MH, Choi EK. The diagnostic criteria for autoimmune chronic pancreatitis: it is time to make a consensus. Pancreas. 2007; 34: 279-86
|
|
|
|
|
|
11) Ryu JK, Chung JB, Park SW, et al. Review of 67 patients with autoimmune pancreatitis in Korea: a multicenter nationwide study. Pancreas. 2008; 37: 377-85
|
|
|
|
|
|
12) Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009; 7: 1097-103
|
|
|
|
|
|
13) Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer？ A prospective outcome study. Gut. 2008; 57: 1704-12
|
|
|
|
|
|
14) Matsushita M, Yamashina M, Ikeura T, et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol. 2007; 102: 220-1
|
|
|
|
|
|
15) Matsushita M, Ikeura T, Fukui T, et al. Refractory autoimmune pancreatitis: azathioprine or steroid pulse therapy？ Am J Gastroenterol. 2008; 103: 1834
|
|
|
|
|
|
16) Otsuki M, Chung JB, Okazaki K, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008; 43: 403-8
|
|
|
|
|
|
17) Ohtsubo K, Watanabe H, Okada G, et al. A case of pancreatic cancer with formation of a mass mimicking alcoholic or autoimmune pancreatitis in a young man. Possibility of diagnosis by hypermethylation of pure pancreatic juice. JOP. 2008; 9: 37-45
|
|
|
|
|
|
18) Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007; 42(Suppl 18): 50-8
|
|
|
|
|
|
19) Park DH, Kim MH, Oh HB, et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008; 134: 440-6
|
|
|
|
|
|
20) Kamisawa T, Okamoto A, Wakabayashi T, et al. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol. 2008; 43: 609-13
|
|
|
|
|
|
21) Hirano K, Asaoka Y, Tada M, et al. No significant relation between relapse of autoimmune pancreatitis and substitution of aspartic acid at position 57 of DQbeta1. J Gastroenterol. 2009; 44: 799-800
|
|
|
|
|
|
22) Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008; 134: 706-15
|
|
|
|
|
|
23) Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol. 2009; 104: 2295-306
|
|
|
|
|
|
24) Frulloni L, Scattolini C, Falconi M, et al. Autoimmune pancreatitis: differences between the focal and diffuse forms in 87 patients. Am J Gastroenterol. 2009; 104: 2288-94
|
|
|
|
|
|
25) Zamboni G, Lüttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004; 445: 552-63
|
|
|
|
|
|
26) 西森 功, 大槻 眞. 自己免疫性膵炎のステロイド治療の可否と再発に関する検討. In: 厚生労働科学研究費補助金 難治性膵疾患に関する調査研究班. 平成19年度総括・分担研究報告書. 東京: アークメディア; 2008. p. 137-44
|
|
|
|
|
|
27) Nishino T, Toki F, Oyama H, et al. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med. 2006; 45: 497-501
|
|
|
|
|
28) Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/ immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009; 7: 1089-96
|
|
|
|
|
|
29) Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008; 6: 364-6
|
|
|
|
|